SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% – Here’s Why

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) were down 8.1% on Friday . The company traded as low as $4.25 and last traded at $4.2650. Approximately 1,706,467 shares changed hands during trading, a decline of 78% from the average daily volume of 7,658,134 shares. The stock had previously closed at $4.64.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday. Maxim Group lifted their price target on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Stock Down 3.5%

The stock has a market capitalization of $804.34 million, a P/E ratio of -17.90 and a beta of 2.22. The business has a fifty day moving average price of $4.80 and a 200-day moving average price of $3.39.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities analysts expect that SELLAS Life Sciences Group, Inc. will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of SELLAS Life Sciences Group

A number of large investors have recently made changes to their positions in the stock. Dagco Inc. purchased a new stake in SELLAS Life Sciences Group in the fourth quarter worth approximately $2,177,000. Everhart Financial Group Inc. bought a new position in shares of SELLAS Life Sciences Group during the 3rd quarter valued at $533,000. Anson Funds Management LP boosted its stake in shares of SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after buying an additional 5,757,938 shares during the last quarter. Opus Capital Group LLC increased its position in SELLAS Life Sciences Group by 26.8% during the fourth quarter. Opus Capital Group LLC now owns 317,100 shares of the company’s stock valued at $1,195,000 after acquiring an additional 67,100 shares during the last quarter. Finally, NORTHSTAR ASSET MANAGEMENT Co lifted its holdings in SELLAS Life Sciences Group by 24.0% in the fourth quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 50,000 shares of the company’s stock valued at $188,000 after acquiring an additional 9,680 shares during the period. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.